search returned 100 results for adalimumab, showing results 61 to 70
to the board to reconsider the prescribing of
methotrexate by NP’s.
12.2 Adalimumab for uveitis...) and they are looking to make a submission to the
PBAC to get adalimumab on the PBS for uveitis
• Most patients with uveitis needing biologic treatment access adalimumab
through the AbbVie
https://rheumatology.org.au/LinkClick.aspx?fileticket=%2fxZA7E0in%2bE%3d
to the board to reconsider the prescribing of
methotrexate by NP’s.
12.2 Adalimumab for uveitis...) and they are looking to make a submission to the
PBAC to get adalimumab on the PBS for uveitis
• Most patients with uveitis needing biologic treatment access adalimumab
through the AbbVie
https://rheumatology.org.au/LinkClick.aspx?fileticket=FERFMjS2VpI%3d
, etanercept, rituximab
• Currently approved, not yet in market- adalimumab (more than one biosimilar brand)
• Infliximab, etanercept and adalimumab biosimilars have been deemed by the PBAC... this driver to also become available for biosimilar forms of adalimumab,
when they come to market
https://rheumatology.org.au/LinkClick.aspx?fileticket=s2uYhpyqu1M%3d
to the board to reconsider the prescribing of
methotrexate by NP’s.
12.2 Adalimumab for uveitis...) and they are looking to make a submission to the
PBAC to get adalimumab on the PBS for uveitis
• Most patients with uveitis needing biologic treatment access adalimumab
through the AbbVie
https://rheumatology.org.au/LinkClick.aspx?fileticket=_xZA7E0in-E%3d&portalid=2
Considerations
Tocilizumab IV
80mg/4mL
RA Yes Yes Multiple
Polyarticular JIA Yes Yes Adalimumab... Yes Multiple
Polyarticular JIA Yes Yes Adalimumab
Etanercept
Systemic JIA Yes No Anakinra... Adalimumab
Etanercept
Systemic JIA Yes No Anakinra
Canakinumab
Alternatives not available
https://rheumatology.org.au/LinkClick.aspx?fileticket=aWDwEOcgN9k%3d
28 March 2025 - Ltr to PBAC re proposed changes to PBS listings for adalimumab for certain...
28 June 2024 - Ltr to PBAC re adalimumab for juvenile AS
28 June 2024 - Ltr to PBAC re adalimumab for JIA
6 May 2024 - Response from PBAC re: listing of adalimumab for immune-mediated
https://rheumatology.org.au/For-Members/My-Portal/ARA-Advocacy/External-Correspondence
of the current
PBS listing is sought
Note
Adalimumab Non-infectious
inflammatory uveitis
(including... on adalimumab for non-infectious intermediate, posterior or panuveitis done by Government
agencies... analysis has therefore shifted considerably. Adalimumab is a highly effective, evidence-
based
https://rheumatology.org.au/LinkClick.aspx?fileticket=SxKNQJaq5Ew%3d
of the current
PBS listing is sought
Note
Adalimumab Non-infectious
inflammatory uveitis
(including... on adalimumab for non-infectious intermediate, posterior or panuveitis done by Government
agencies... analysis has therefore shifted considerably. Adalimumab is a highly effective, evidence-
based
https://rheumatology.org.au/LinkClick.aspx?fileticket=SxKNQJaq5Ew%3d&portalid=2
review (see
agenda item 11)
• WR advised that he has drafted an evidence-based letter on adalimumab...
Agenda Item
13 March PBAC 2024 Meeting Agenda items to submit comments
• Adalimumab for vision... as biologic.
ACTIONS:
• As discussed above.
• WR to draft adalimumab for vision threatening
https://rheumatology.org.au/LinkClick.aspx?fileticket=BwHiBtwd0MM%3d
review (see
agenda item 11)
• WR advised that he has drafted an evidence-based letter on adalimumab...
Agenda Item
13 March PBAC 2024 Meeting Agenda items to submit comments
• Adalimumab for vision... as biologic.
ACTIONS:
• As discussed above.
• WR to draft adalimumab for vision threatening
https://rheumatology.org.au/LinkClick.aspx?fileticket=BwHiBtwd0MM%3d&portalid=2